Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PKM | P14618 | 1/20 | 0.56 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.51 |
| ▸ | HPGD | P15428 | 1/20 | 0.49 |
| ▸ | MEN1 | O00255 | 3/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.48 |
| ▸ | NPC1 | O15118 | 3/20 | 0.47 |
| ▸ | RAB9A | P51151 | 2/20 | 0.47 |
| ▸ | CES2 | O00748 | 1/20 | 0.47 |
| ▸ | CES1 | P23141 | 1/20 | 0.47 |
| ▸ | PTGIR | P43119 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | GLA | P06280 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL698882 | 0.88 | ADRA2C (0.64) | ADRA2CHPGDMEN1KMT2ANPC1 | |
| SCHEMBL9809224 | 0.85 | HPGD (0.66) | PKMHPGDMEN1KMT2AALDH1A1 | |
| SCHEMBL9716677 | 0.85 | ADRA2C (0.53) | ADRA2CHPGDMEN1KMT2ANPC1 | |
| SCHEMBL9716701 | 0.83 | ADRA2C (0.55) | ADRA2CHPGDMEN1KMT2ANPC1 | |
| SCHEMBL6174036 | 0.83 | ADRA2C (0.51) | ADRA2CHPGDMEN1KMT2ANPC1 | |
| SCHEMBL10660695 | 0.83 | BACE1 (0.52) | ADRA2CHPGDMEN1KMT2ANPC1 | |
| SCHEMBL6570858 | 0.83 | KDM4E (0.63) | ADRA2CHPGDMEN1KMT2ANPC1 | |
| SCHEMBL4008336 | 0.82 | HPGD (0.59) | PKMHPGDKMT2ANPC1RAB9A | |
| SCHEMBL1928093 | 0.82 | PKM (0.54) | PKMADRA2CHPGDMEN1KMT2A | |
| SCHEMBL12031549 | 0.82 | NPC1 (0.67) | PKMMEN1KMT2ANPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-9124595-A | — | — | None | — | — | JP | disclosed |
| EP-0838448-B1 | Process for the separation of a mixture of enantiomers | DSM IP ASSETS BV (NL) | 2004-04-21 | — | — | EP | disclosed |
| US-6465684-B2 | DIASTEREOMER COMPLEX OF AT LEAST THREE COMPOUNDS, AT LEAST ONE IS A RESOLVING AGENT IN OPTICALLY ACTIVE FORM, AND AT LEAST ONE IS AN ENANTIOMER IN OPTICALLY ACTIVE FORM; RAPID SEPARATION | DSM N.V. (NL) | 2002-10-15 | — | — | US | disclosed |
| US-20010051747-A1 | Process for the separation of a mixture of enantiomers | DSM N.V. | 2001-12-13 | — | — | US | disclosed |
| US-6235927-B1 | OPTICAL RESOLUTION OF ENANTIOMORPHS OF COMPLEXES | DSM N.V. (NL) | 2001-05-22 | — | — | US | disclosed |
| EP-0838448-A1 | Process for the separation of a mixture of enantiomers | DSM N.V. (NL) | 1998-04-29 | — | — | EP | disclosed |
| JP-H09124595-A | REAGENT FOR OPTICAL RESOLUTION AND PRODUCTION OF OPTICALLY ACTIVE 3-AMINOPYRROLIDINE DERIVATIVE | TORAY IND INC | 1997-05-13 | — | — | JP | disclosed |
| EP-0178911-B1 | COMPOSITION CONTAINING A PENEM OR CARBAPENEM ANTIBIOTIC | SANKYO COMPANY LIMITED (JP) | 1992-01-22 | — | — | EP | disclosed |
| US-4757066-A | Reduces renal toxicity | SANKYO COMPANY LIMITED (JP) | 1988-07-12 | — | — | US | disclosed |
| EP-0178911-A2 | Composition containing a penem or carbapenem antibiotic | SANKYO COMPANY LIMITED (JP) | 1986-04-23 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010051747-A1 | Process for the separation of a mixture of enantiomers | EPHX2, VKORC1, ALDH1A2 | PKM 2297/4885ADRA2C 688/4885HPGD 695/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.